Where the advertising budgets of pharmaceutical companies dwarf their R&D budgets, is there not an argument for the Government to look again at the tax position of those companies, as well as at the price of their products?
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Steve McCabe
(Labour)
in the House of Commons on Monday, 24 October 2016.
It occurred during Debate on bills on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
616 c85Session
2016-17Chamber / Committee
House of Commons chamberSubjects
Librarians' tools
Timestamp
2022-05-10 14:19:25 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000033
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000033
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000033